Bright Minds Biosciences Stock Return On Asset
| DRUG Stock | USD 33.75 1.07 3.07% |
Fundamental analysis of Bright Minds allows traders to better anticipate movements in Bright Minds' stock price by examining its financial health and performance throughout various phases of its business cycle.
The current Return On Assets is estimated to decrease to -0.55. Bright | Return On Asset | Build AI portfolio with Bright Stock |
Bright Minds Biosciences Company Return On Asset Analysis
Bright Minds' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Bright Minds Return On Asset | -0.11 |
Most of Bright Minds' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bright Minds Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bright Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Bright Minds is extremely important. It helps to project a fair market value of Bright Stock properly, considering its historical fundamentals such as Return On Asset. Since Bright Minds' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bright Minds' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bright Minds' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Bright Total Assets
Total Assets |
|
Based on the latest financial disclosure, Bright Minds Biosciences has a Return On Asset of -0.1057. This is 98.79% lower than that of the Biotechnology sector and 99.55% lower than that of the Health Care industry. The return on asset for all United States stocks is 24.5% lower than that of the firm.
Bright Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bright Minds' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bright Minds could also be used in its relative valuation, which is a method of valuing Bright Minds by comparing valuation metrics of similar companies.Bright Minds is currently under evaluation in return on asset category among its peers.
Bright Minds Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bright Minds from analyzing Bright Minds' financial statements. These drivers represent accounts that assess Bright Minds' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bright Minds' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 53.9M | 61.4M | 9.5M | 734.8K | 845.0K | 802.8K |
Bright Minds ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.Environmental | Governance | Social |
Bright Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 200.26 M | ||||
| Shares Outstanding | 7.08 M | ||||
| Shares Owned By Insiders | 22.54 % | ||||
| Shares Owned By Institutions | 74.81 % | ||||
| Number Of Shares Shorted | 169.04 K | ||||
| Price To Book | 5.89 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (2.8 M) | ||||
| Cash And Equivalents | 8.64 M | ||||
| Cash Per Share | 0.71 X | ||||
| Total Debt | 118.96 K | ||||
| Current Ratio | 22.88 X | ||||
| Book Value Per Share | 7.87 X | ||||
| Cash Flow From Operations | (1.85 M) | ||||
| Short Ratio | 2.74 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 94.27 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 247.53 M | ||||
| Total Asset | 6.1 M | ||||
| Retained Earnings | (34.35 M) | ||||
| Working Capital | 5.46 M | ||||
| Net Asset | 6.1 M |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Bright Minds Piotroski F Score and Bright Minds Altman Z Score analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.